Changes in Aortic Valve Signal Heart Failure Progression
METHODOLOGY:
Researchers in Italy retrospectively analysed data of 1397 patients with chronic HF (mean age, 65.2 years; 83.4% men) enrolled between September 2006 and December 2019 to determine whether AV sclerosis can predict mortality and cardiovascular outcomes.
The patients had a history of HF with reduced ejection fraction or left ventricular ejection fraction < 40%, had stable HF medications for at least 3 months, could perform a cardiopulmonary exercise test, and had no planned major interventions.
The presence of AV sclerosis was identified using images from transthoracic echocardiography.
The 5-year outcomes of interest were all-cause mortality and cardiovascular outcomes involving a composite of cardiovascular mortality, urgent heart transplant, or implantation of the left ventricular assist device.
TAKEAWAY:
At baseline, 50.6% of patients had AV sclerosis; they were older and had a higher incidence of ischaemic HF and more severe HF, had worse renal function, and received more medical and device treatments than those without the condition.
The presence of AV sclerosis at the time of HF diagnosis was linked to higher risks for all-cause mortality and cardiovascular outcomes; however, this association disappeared after adjusting for confounding factors.
Among patients with follow-up echocardiograms, more than 40% developed AV sclerosis, particularly those older in age, with more severe HF, and with ischaemic cardiomyopathy and/or diabetes.
Developing AV sclerosis during follow-up was associated with markedly higher risks for all-cause mortality (hazard ratio [HR], 3.7; P = .017) and cardiovascular outcomes (HR, 6.0; P = .020).
IN PRACTICE:
"Detecting the presence and new development of AV sclerosis could assist physicians in early identifying HF patients who may benefit most from closer clinical follow-up, more intensive therapy, and stricter risk factor control," the authors wrote.
SOURCE:
This study was led by Veronika A. Myasoedova, MD, PhD, Centro Cardiologico Monzino, Milan, Italy. It was published online on June 06, 2025, in European Heart Journal Open .
LIMITATIONS:
This retrospective study included only patients who could undergo cardiopulmonary exercise testing, thus limiting the generalisability of the findings to those with more advanced HF. Follow-up echocardiography was available for only 55% of patients. AV sclerosis was expressed as either present or absent without any grading.
DISCLOSURES:
This study received support from the Italian Ministry of Health funds and Fondazione Gigi e Pupa Ferrari Onlus. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market" report has been added to global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to and IBD are types of gastrointestinal diseases. The pathophysiology of both diseases is unknown and is believed to be influenced by environmental factors, ethnicity, dietary habits and genetic predisposition. Due to varied symptoms, patients must use multiple therapeutics simultaneously. Therapeutics aim to improve patients' quality of life and achieve clinical remission for the longest period key businesses in the IBS therapeutics market include Ironwood Pharmaceuticals, AstraZeneca, AbbVie, Abbott and Allergan. In the IBD therapeutics market, corporations include AbbVie, Johnson & Johnson Services Inc., Amgen and Biogen. Start-up companies are increasingly entering the IBS and IBD therapeutics market with novel pipeline candidates. Global pharmaceutical companies, such as AbbVie and Amgen, are focused on label expansion studies and licensing collaborations with small businesses to develop and market products. Report ScopeThe report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class. The IBD therapeutics segment is further segmented based on type and drug class. The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also report includes: 142 data tables and 54 additional tables Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors Insights derived from Porter's Five Forces model, as well as global supply chain analysis Patent analysis, featuring key granted and published patents Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc. Key Attributes: Report Attribute Details No. of Pages 155 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $33.3 Billion Forecasted Market Value (USD) by 2030 $52.6 Billion Compound Annual Growth Rate 9.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Inflammatory Bowel Disease Irritable Bowel Syndrome Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market Impact of U.S. Tariffs Macroeconomic Factor Analysis Population Demographics and Aging Populations Government Policies on Drug Prices Chapter 3 Market Dynamics Market Drivers Rising Prevalence of Gastrointestinal Disorders Increasing Entry of Biologics and Biosimilars Market Restraints Side Effects and Ceiling Impact of Biologics Overlap with Other Gi Disorders Use of Alternative Treatment Approaches Market Opportunities Self-Administered Drugs Personalized Therapies Chapter 4 Regulatory Landscape Regulatory Aspects of IBS and IBD Therapeutics The U.S. European Union Asia-Pacific Chapter 5 Emerging Technologies and Pipeline Analysis Key Takeaways Emerging Technologies Novel Target-based Small-Molecule Drugs Microbiome-based Therapeutics Advanced Combination Treatments AI for Drug Discovery Pipeline Analysis Chapter 6 Market Segmentation Analysis Market Analysis by Disease Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Drug Class Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Key Takeaways Industry Structure Company Share Analysis of the IBD Therapeutics Market Competitive Share Analysis of the IBS Therapeutics Market Strategic Analysis Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective Introduction to ESG ESG Risk Ratings Company Profiles Abbvie Inc. Amgen Inc. Astrazeneca Bayer AG Biogen Bristol-Myers Squibb Co. Gilead Sciences Inc. Ironwood Johnson & Johnson Services Inc. Lilly Merck & Co. Inc. Pfizer Inc. Sanofi Takeda Pharmaceutical Co. Ltd. UCB For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Some Ontario hospitals offering hefty incentives for locums amid doctor shortage
As a travelling physician in northern Ontario, Dannica Switzer is acutely aware of the health-care crisis in underserved communities. 'It's sad to see how much worse things can get,' said Switzer, who works as a locum, filling roles on a temporary basis in rural or remote areas. Switzer has been in high demand since returning to locum work after quitting her family practice in Wawa, Ont., due to burnout more than two years ago. Rural and northern Ontario hospitals are competing to recruit locums by offering hefty financial incentives amid a severe shortage of doctors that has plagued the health-care system. The hospitals are vying for doctors from a relatively small pool of locums, often as a way to prevent emergency department closures that have become more common in recent years. 'But the reality is that most people are booked,' Switzer said in a recent interview. 'And even if you really want to go help that town out to prevent the closure, you can't because you're already working somewhere else.' Hospitals' fierce competition for locum recruitment has triggered concerns about equitable access to health care, with some doctors and experts saying it leaves smaller communities and hospitals vulnerable because they may not have the financial resources needed to entice physicians. While funding mainly comes from provincial programs, some hospitals top up the pay for locum shifts by tapping into their operating budgets or money that's available due to vacant staff positions. But Mike Cotterill, a physician in Wawa and one of Switzer's former colleagues, said that approach is not ideal. 'If you top up with X dollars, then the next town down the road will top up with X plus, you know, X plus Y," he said in an interview. 'So, it's a competition that is bad for hospitals and bad for towns. It really shouldn't have to happen." He said the Lady Dunn Health Centre, where he works, has so far avoided having to top up the pay for locums and its "excellent" recruiter has been able to ensure a steady supply of such physicians. But that's not the case at some other hospitals. Timmins and District Hospital is currently offering up to $18,500 for hospitalist medicine locums to work there for one week in August, according to an ad posted on the hospital's social media page. The North Bay Regional Health Centre pays up to $2,700 per eight-hour shift for emergency medicine locums, according to its website. Manitoulin Health Centre's Little Current site offers $250 per hour to physicians who take ER shifts in July and August. The hospital receives around $160 per hour from the Health Ministry for night and weekend shifts and tops up that amount so it can stay 'competitive," using funds from unfilled positions at the hospital, said lead physician Anne McDonald. The generous pay, flexible scheduling and less administrative work that comes with being a locum may impede some hospitals' recruitment and retention of full-time doctors, some experts say. The financial incentives for locums, which can also include accommodation, flights, car rentals and other expenses, are unaffordable in the long run, they add. The goal should be to make permanent positions more appealing so that doctors stay in communities, Switzer said. "We cannot recruit our way out of a retention crisis," she said. Still, doctors agree that locums play a vital role in rural and northern areas of the province. "We absolutely need the locum and the local program," said Dr. Anjali Oberai, who works in Wawa alongside Cotterill, her husband. 'We need to support locums but if the support is such that it de-incentivizes working and living in community, yeah, then we have a problem." Oberai and Cotterill worked for nearly two years as locum doctors to take advantage of the lifestyle before settling down in Wawa in 1998. But "the locum landscape was quite different back then,' Oberai said. They worked mainly during the summer, covering for doctors who were on vacation or other short-term leaves. But locums are now often used to fill vacant positions, and they've helped Wawa keep its hospital and primary care centre operational during a worsening physician shortage in the community in recent years. McDonald, the lead doctor at Manitoulin Health Centre's Little Current site, said rural doctors are under a lot of pressure, taking care of patients who are often their neighbours, friends or relatives due to physician shortages. Some cannot handle that workload and become locums instead. "I really think the locum lifestyle is less about the money exactly and more about the lack of burden of ongoing responsibilities that weighs physicians down," McDonald said. There are more than 350 physician vacancies in northern communities, according to the Ontario Medical Association. That shortage might get even worse as nearly half of the doctors there are expected to retire in the next five years. The association always advocates for a system that encourages doctors to provide reliable and continuous care at a specific location, OMA president Zainab Abdurrahman said. But the doctor shortage is so acute that locums have become an essential part of the system. "It's not that having a locum means you're not hiring and you're not actively trying to recruit,' she said. Some new medical school graduates want to take time to explore their options as the financial cost and administrative burden of setting up a practice holds them back, she said, while others want to become locums to help underserved communities. While financial incentives offered by some hospitals do lead to inequities, they are just a symptom of a larger issue, Abdurrahman said. 'The utilization of these kind of extra incentives is really a reflection of the desperation in the health-care system,' she said. 'People are making choices to be competitive because they're feeling the constraint.' The Health Ministry says its Rural Emergency Medicine Coverage Investment Fund, which replaced the Temporary Locum Program in April, is helping hospitals improve access to emergency care throughout the year by offering them the flexibility to hire locums and improve their capacity to recruit permanent doctors. That commitment came out of negotiations between the government and the OMA for a new Physician Services Agreement. Ministry spokesperson Ema Popovic also pointed to the province's investments aimed at connecting every Ontarian with a primary care provider by 2029, and efforts to add hundreds of seats in medical schools. Many doctors say that other incentives, such as improving access to education, more vacation time and less administrative paperwork, are also needed to recruit and retain full-time physicians. For Switzer, being a locum gives her more control over her schedule but that comes with a cost. 'I have a house, I'm not at it. I have a garden. I'm not there ... I miss a lot of moments with my family," she said. This report by The Canadian Press was first published July 31, 2025. Sharif Hassan, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
26 minutes ago
- Forbes
Your Pet's Topical Flea Treatments Harm Wildlife
If you have any itchy dog or cat, you may reach for familiar topical flea treatments like Frontline, Advantage, or PetArmor. These products promise pets fast, easy protection from fleas and ticks. Unfortunately, this convenience comes at a hidden environmental cost. Two pesticides, fipronil and imidacloprid, are typically the active ingredients in topical treatments. These same compounds were banned from agricultural use in parts of Europe and California because they are so harmful to bees and other pollinators. Yet we're still smearing these pesticides on our pets, and they are showing up in rivers and streams across the country. Flea-Killing Chemicals End Up In Waterways Topical flea treatments are designed to stay on a pet's skin and fur, but that also means they can easily wash off into household drains or outdoor water bodies. Earlier this year, a study from the University of Sussex found that dogs can continue shedding fipronil into the environment for up to 28 days after a single treatment. They further found that a single treated dog swimming in a small pond raised pesticide concentrations above safety thresholds. Pet swimming isn't the only concern. In fact, the primary route of contamination appears to be everyday activities like washing hands after applying the product, bathing pets, and laundering pet bedding. These actions send pesticide-laced water into treatment plants that are not designed to remove such compounds. One study from the California Environmental Protection Agency found fipronil in wash water from dogs treated weeks earlier. Regardless of their filtration technology, conventional wastewater treatment facilities allow these chemicals to pass through, discharging them directly into rivers, bays, and oceans. Wildlife Is Paying the Price For Pets' Fleas Fipronil and imidacloprid are extremely toxic to aquatic invertebrates. In some cases, exposure to even tiny amounts can kill freshwater shrimp and insect larvae or impair their ability to survive and reproduce. A study by the San Francisco Estuary Institute (SFEI) found fipronil in all tested sewage treatment plants at concentrations above the U.S. Environmental Protection Agency's recommended limit for aquatic ecosystems. Imidacloprid was also found at levels between 84 and 305 parts per trillion, well above the limit of 10 parts per trillion. Water and sediment samples from San Francisco Bay show pesticide levels near or above toxicity thresholds for invertebrates. According to Dr. Rebecca Sutton of SFEI, 'that's the base of our food web. So, if those critters experience impacts, it could go up and harm our fish and our wildlife.' The contamination doesn't stop with water. Another study led by the University of Sussex found fipronil in every single bird nest examined. Imidacloprid and permethrin were found in 89 percent. Birds often use pet fur to line their nests, exposing their eggs and chicks to these neurotoxins. The researchers linked this exposure to lower hatching success and higher chick mortality rates. Safer Flea Solutions Are Already Available Veterinarians increasingly recommend oral flea and tick medications, which are safer for the environment. These treatments are metabolized internally, meaning there is no pesticide residue left on pet fur to wash off into water systems. Some options include: If you must use topicals, avoid unnecessary treatments and consider seasonal use instead of year-round application. You can ask your vet about the monthly topical Revolution or the quarterly topical Bravecto. You should also keep treated pets out of natural water sources for at least 28 days after topical application. To reduce the risk of fleas in the first place, you can vacuum your home and your pet's bedding often (and empty the bag). See more tips for pet owners and veterinarians about chewable flea and tick medications from San Francisco Bay Area wastewater agencies. Flea Treatment Market Is Ripe For Innovation Though safer options exist, companies should innovate to find more solutions that protect our pets without polluting the planet. The flea and tick treatment market is valued at 9.7 billion dollars globally in 2024 and is projected to grow to 14.8 billion by 2034. For companies willing to act, this presents a strategic advantage. Brands that lead on safety, sustainability, and transparency will be well positioned as consumer awareness catches up with the science. The health of our pets and the health of our planet are linked, and both deserve better.
